TARA insider buying and SEC filings, explained
Protara Therapeutics, Inc. · CIK 1359931
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$125K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Apr 8, 2026 | Planned (10b5-1) | Jacqueline Zummo (Chief R&D Officer) sold 1,134 shares at $5.40 ($6K), marked as a 10b5-1 plan trade. Holdings down 1% to 94,827 shares. | SEC filing Filed Apr 9, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Jacqueline Zummo (Chief R&D Officer) sold 22,598 shares at about $5.26 ($119K), marked as a 10b5-1 plan trade. Holdings down 19% to 95,961 shares. | SEC filing Filed Apr 2, 2026 |
25 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TARA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.